FDA unveils regulatory science plan

Kondro, Wayne
September 2011
CMAJ: Canadian Medical Association Journal;9/20/2011, Vol. 183 Issue 13, pE1014
Academic Journal
The article reports that the U.S. Food and Drug Administration (FDA) has unveiled their "Advancing Regulatory Science at FDA" strategic plan to improve their capacity to oversee drug, biologics, and medical devices development safety. It says that the plan contains methods to measure human susceptibility to drug side affects, assess clinical trial design, and determine human risk. Also included are the eight priority areas of the FDA like toxicology modernization, and clinical evaluations.


Related Articles

  • FDA to Silence 'Noise' from too Many Adverse Events. Serebrov, Mari // BioWorld Today;3/28/2011, Vol. 22 Issue 59, p1 

    This article reports on the plan of the U.S. Food and Drug Administration (FDA) to reduce cases of the overreporting of individual serious adverse events in clinical trials. The FDA will address adverse effects of investigational new drugs (INDs) and biologics. The agency plans to develop a rule...

  • Two Smoking Cessation Drugs Will Now Come With Warning.  // Chain Drug Review;7/20/2009, Vol. 31 Issue 12, p104 

    The article reports on the move of the U.S. Food and Drug Administration (FDA) to require manufacturers to put a boxed warning on the prescribing information for smoking cessation drugs Chanix and Zyban in Washington. It mentions that the warning will serve as a foreground on the risks involved...

  • The Deception and Fallacies of Sponsored Randomized Prospective Double-Blinded Clinical Trials: The Bisphosphonate Research Example. Marx, Robert E. // Oral & Craniofacial Tissue Engineering;Summer2012, Vol. 2 Issue 2, p93 

    The randomized prospective double-blinded clinical trial (RCT) is accepted as Level I evidence and is highly regarded. However, RCTs that gained FDA approval of drugs such as Vioxx, Fen- Phen, and oral and intravenous bisphosphonates have proven to generate misleading results and have not...

  • Tanning Bonus. Jaroff, Leon // Time International (South Pacific Edition);06/28/1999, Issue 26, p65 

    States a group of men in clinical trial for the drug Melanotan, a synthetic form of the natural hormone Alpha MSH, experienced spontaneous erections after being given injections of the drug. Efforts to design tests of two groups of sexually dysfunctional man; How the drug works; Outcome of...

  • Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety. Dell'Utri, Chiara; Digesu, G.; Bhide, Alka; Khullar, Vik // International Urogynecology Journal;Oct2012, Vol. 23 Issue 10, p1337 

    Introduction and hypothesis: This is a systematic review of clinical data assessing the safety, efficacy and tolerability of fesoterodine in randomised control trials (RCTs) in the treatment of overactive bladder (OAB). Methods: We performed a MEDLINE literature search of articles published...

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk. Elliott, William T. // Clinical Cardiology Alert;Jul2007 Pharmacology Watch, p1 

    The article reports on a black box warning that will be receive by GlaxoSmithKline's rosiglitazone (Avandia) from the U.S. Food & Drug Administration (FDA) because of concerns over heart failure associated with use of the drug. The other drug that will be subjected to a black box warning is...

  • InterMune's CRL Response Highlights Pros, Cons of IPF. Orelli, Brian // BioWorld Insight;6/6/2011, Vol. 19 Issue 23, p1 

    The article discusses the complete response letter (CRL) from InterMune Inc. which highlights the positive and negative effects of the drug Esbriet for the treatment of idiopathic pulmonary fibrosis (IPF). It notes that the plan for the confirmatory trial for the drug was required to obtain an...

  • Web-Based Patient-Reported Outcomes in Drug Safety and Risk Management: Challenges and Opportunities? Banerjee, Anjan K.; Ingate, Simon // Drug Safety;2012, Vol. 35 Issue 6, p437 

    Patient-reported outcomes (PROs) from web-based sources are becoming increasingly important, providing opportunities for industry and regulators to understand the benefits and risks of medicines in a real-world context. Although some guidance exists for the use of adverse event (AE) reports from...

  • NEWSLINE.  // Monthly Prescribing Reference;Sep2010, Vol. 26 Issue 9, pA9 

    The article offers news briefs related to drugs. Labopharm and Angelini have made the drug Oleptro available for major depressive disorder (MDD). The U.S. Food and Drug Administration (FDA) is examining clinical trial data suggesting that Stalevo from Novartis increased the risk for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics